Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.
暂无分享,去创建一个
A. Hauschild | M. Ross | I. Puzanov | C. Garbe | M. Milhem | F. Collichio | J. Chesney | R. Andtbacka | Jenny J. Kim | Lisa Chen